高级检索
当前位置: 首页 > 详情页

PARP1 Gene Polymorphisms and the Prognosis of Esophageal Cancer Patients from Cixian High-Incidence Region in Northern China.

文献详情

资源类型:
Pubmed体系:
机构: [1]Hebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Hebei Province, China. [2]Department of Surgery, Shijiazhuang Ping’an Hospital, Hebei Province, China.
出处:
ISSN:

关键词: Poly(ADP-ribose) polymerase 1- polymorphism- prognosis- survival- esophageal squamous cell carcinoma

摘要:
Poly (ADP-ribose) polymerase 1 (PARP1), as a key enzyme in the base excision repair pathway, plays a crucial role in tumorigenesis and progression. This study aimed to assess whether polymorphisms of PARP1 gene could be used as predictive biomarkers for the survival of esophageal squamous cell carcinoma (ESCC) patients from Cixian high-incidence region in northern China. In 203 ESCC patients with survival information, PARP1 rs1136410 T/C and rs8679 T/C single nucleotide polymorphisms (SNPs) were genotyped by polymerase chain reaction ligase detection reaction (PCR-LDR) method. All statistical analyses were performed using the SPSS ver. 22.0 software package (SPSS, Chicago, IL, USA). The mean age ± standard deviation of the ESCC patients was 60.4 ± 7.9 years. There was no significant relation of sex, age, smoking status and upper gastrointestinal cancer family history with the survival time of the ESCC patients. The mean survival time of rs1136410 T/T, T/C and C/C genotype carriers were 43.3, 42.3 and 46.6 months, respectively. The rs1136410 was not associated with the survival time of the ESCC patients. For rs8679, the mean survival time of T/T genotype carriers was 43.7 months, which was not significantly different from that of the patients with T/C genotype (42.1 months). In Cixian high-incidence region from northern China, rs1136410 and rs8679 SNPs might not be used to predict survival of ESCC patients. There is a need to explore whether other SNPs of PARP1 gene have an effect on prognosis of ESCC patients.

基金:
语种:
PubmedID:
第一作者:
第一作者机构: [1]Hebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Hebei Province, China.
通讯作者:
通讯机构: [1]Hebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Hebei Province, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号